Ironwood Poised To Move Linaclotide To Phase III In IBS-C
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With a pair of pivotal Phase III trials in chronic constipation under way, Ironwood Pharmaceuticals reported success Oct. 7 in Phase IIb testing of linaclotide in constipation-predominant irritable bowel syndrome. Partnered in the U.S. with Forest Laboratories, the firm plans to begin two pivotal Phase III trials in IBS-C by next January